Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
NCT01254123 on ClinicalTrials.gov · last registry update 2010-12-06
A small phase 3 — 40 participants, against a typical 424. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Amsterdam UMC, location VUmc
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2009-11
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Safety of GLP-1 receptor agonist Exenatide infusion compared to placebo in patients with an acute myocardial infarction undergoing primary PCI
Conditions studied
Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.